Work

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors

Year: 2015

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-015-2693-z

Authors: David M. Hyman, Alexandra E. Snyder, Richard D. Carvajal, John F. Gerecitano, Martin H. Voss, Alan L. Ho, Jason Konner, Jennifer L. Winkelmann, Megan A. Stasi, Kelsey R. Monson, Alexia Iasonos, David R. Spriggs, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Nora Katabi, Matthew G. Fury

Institutions: Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Memorial Sloan-Kettering Cancer Center, National Cancer Institute

Awards: G589551644, Cancer Center Support Grant

OpenAlex ID: W2022847648

FWCI: 1.543

Cites: 28

Cited by: 21

Related to: 10